New Date for Median Technologies’ Webcasts: February 1st, 2024
26 Jan 2024
SOPHIA-ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA/SME eligible) announced today that Fredrik Brag, CEO and Founder of Median Technologies, will provide a company update on February 1, 2024:
Webcast held in English: at 4:30 pm CET / 10:30 am ET
> Registration link
Webcast held in French: at 6:00 pm CET / 12:00 pm ET
> Registration link
Webcast replays will be available on Median’s corporate website after the live sessions.
About Median Technologies: Pioneering in innovative imaging solutions and services, Median Technologies harnesses cutting-edge AI to elevate the accuracy of early cancer and metabolic disease diagnoses and treatments. Median's offerings, including iCRO for medical image analysis and management in oncology trials and eyonis™, AI/ML tech-based suite of software as medical devices (SaMD), empower biopharmaceutical entities and clinicians to advance patient care and expedite novel therapies. Since its inception, the French-based company, with a presence in the U.S. and China, has been recognized as an "Innovative company" by BPI France and trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is eligible for the French SME equity savings plan scheme (PEA-PME). For more information: www.mediantechnologies.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.